Skip to main content
Erschienen in:

01.09.2022 | editorial

Molecular profiling leading to personalized cancer treatment

verfasst von: Ap. Prof. PDin Dr.in med.univ.et Dr.in scient. med. Barbara Kiesewetter

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Excerpt

Personalized medicine and molecular profiling represent inseparable terms. Only with the broad applicability and low-level access to genomics and next generation sequencing techniques has it been possible to implement precision medicine in the daily routine of medical oncology. In fact, the increasing feasibility of not solely tissue biopsies but also less invasive liquid biopsies is currently again offering new opportunities. As of 2022, molecular tumor profiling on (archived) formalin-fixed, paraffin-embedded (FFPE) tissues using DNA/RNA sequencing techniques allows identification of a wide number of cancer growth-related mutations and fusions that may proceed to treatment planning. However, we had to learn in the past that even if a druggable target exists, it is not given that it (1) is a defined driver of the distinct disease and (2) is clinically significant in the specific setting. Consequently, molecular profiling requests not only the technical abilities to perform such testing but also deep and concise understanding of the target, corresponding drugs, and tumor biology. Furthermore, we need to distinguish clinical settings where no standard is available and next generation sequencing is used to identify potential further therapies, such as in the relapsed/refractory setting after exhaustion of evidenced-based therapies (with multiple successful examples previously published, e.g., the Austrian example set in the EXACT trial by Prager G et al. [1]), versus settings where molecular targeted treatments are essential to the standard treatment algorithm. For the latter, EGFR-driven therapies in lung cancer constitute one of the earliest successful applications and recently a number of novel targeted drugs were approved in lung cancer, including KRAS, MET, and RET inhibitors. Hence, for both the salvage setting and increasingly for approved standard treatments, molecular profiling is crucial for optimal patient management. …
Literatur
3.
Zurück zum Zitat Mateo J, et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol. 2018;29(9):1895–902.CrossRef Mateo J, et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol. 2018;29(9):1895–902.CrossRef
Metadaten
Titel
Molecular profiling leading to personalized cancer treatment
verfasst von
Ap. Prof. PDin Dr.in med.univ.et Dr.in scient. med. Barbara Kiesewetter
Publikationsdatum
01.09.2022
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2022
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-022-00831-8

Weitere Artikel der Ausgabe 3/2022

memo - Magazine of European Medical Oncology 3/2022 Zur Ausgabe